Type 2 Diabetes Mellitus (T2D) and Chronic Kidney Disease (CKD)
Conditions
Brief summary
This study is being carried out in 4 countries (France, Italy, Spain and the UK) to understand the clinical care pathway of population living with type 2 diabetes who also have evidence of chronic kidney disease. The primary objective is to describe the population with T2D and CKD in terms of demography, clinical characteristics and medication use by CKD stage.
Interventions
OTHERNo tretament given
No treatment given
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adults (18 years old or older) diagnosed with T2D and treated with an antidiabetic medication before or at index date, set up on 1 January 2021 2. With evidence of Kidney damage before or at index date: 1. diagnosed with CKD 2. or with a record of eGFR below 60 ml/min/1.73 m\^2 3. or with a record of uACR above 30 mg/g 3. Consulting a GP (all countries) or an Endocrinologist (France, Spain, Italy) or a Nephrologist (Spain) of the THIN® network.
Exclusion criteria
1. aged less than 18 years old at index date 2. less than 360 days prior index date 3. less than 360 days after index date
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of various CKD stages among patients with type 2 diabetes in the THIN database | From the registration date to 1 January 2021 | * Distribution of CKD stages, as determined by eGFR, in patients with and w/out CKD diagnosis * (+/- ACD-10 code for CKD) in cohort of patients diagnosed with T2D. |
Countries
India
Outcome results
None listed